BioPharma
338 followers 24 статия/седмица
Neurogene secures $200M ahead of anticipated study readout

The news led to a stock surge on expectations that forthcoming data for the company’s experimental gene therapy for Rett syndrome may turn out positive.

Mon Nov 4, 2024 19:26
Viking data provide latest test of oral obesity drug potential

Wall Street analysts were impressed by data showing competitive rates of weight loss for Viking’s therapy, but shares in the company still slipped.

Mon Nov 4, 2024 18:58
Novo inks Ascendis deal to develop long-acting GLP-1, other metabolic drugs

Per terms, Novo could pay up to $285 million in upfront and milestone fees to Ascendis, which specializes in a kind of drug-enhancing technology.

Mon Nov 4, 2024 18:58
Empowering versatile applications of digital PCR with standardized, validated assays

Bio-Rad’s extensive ddPCR assay offerings help researchers leverage the full power of digital PCR.

Mon Nov 4, 2024 12:12
Centers of excellence or product-centric BizDevOps managed services?

As novel therapeutics become more complex — and costly — to bring to market, drug developers are looking to unified clinical development platforms to streamline operations.

Mon Nov 4, 2024 12:12
Novo, with new results, to seek approval for obesity drug in MASH

The Phase 3 findings position semaglutide to become the first drug of its kind for the liver disease. But they also confirm GLP-1s aren't a "silver bullet" for MASH, one analyst argued. 

Fri Nov 1, 2024 17:19

Създайте своя емисия с новини

Готови ли сте да опитате?
Стартирайте 14-дневен пробен период, не се изисква кредитна карта.

Създаване на акаунт